Neonatal pressure ulcers: prevention and treatment

Abstract: Health professionals should be prepared to respond to the needs of hospitalized neonates. The health team must consider multiple situations, where the neonate is at risk of having an adverse effect. One of the main interventions that health professionals must practice when interacting with hospitalized newborns is skin care. Neonates often suffer from diaper rash or intravenous drugs extravasation. Recently, hospitalized neonates and especially those in an unstable clinical situation are also at a risk of developing pressure ulcers. The presence of a pressure ulcer in a neonate can lead to serious problems to survival (e.g., sepsis, clinical instability). This is the reason why, with this literature review, we attempt to answer questions from health professionals caring for neonates about the prevention and treatment of pressure ulcers.

Keywords: infant, pressure ulcer, treatment, prevention, wound, assessment

Introduction

Until recently, the pediatric and neonatal populations were not considered to be at risk of pressure ulcers (PUs). They were considered to be free from PUs, since these were associated with adults. Newborns (NB) were not considered at risk of developing PUs due to the relative ease of being repositioned by health professionals. Thus, the development of PUs in hospitalized neonates was attributed to specific causes of therapeutic interventions, considering this adverse effect as unavoidable. Nevertheless, there is now an emerging awareness that acute and immobilized patients, including neonates, are at risk of developing PUs. Most of the prevention and treatment protocols available for neonatal population are based on adult clinical practice, regardless of the anatomical and physiological difference between adults and neonates. It is necessary to implement preventive and treatment measures adapted to the neonatal age. But first, we must explain which characteristics make NBs vulnerable to the presence of PUs.

Skin characteristics of premature and healthy NBs

After delivery, the skin of the term NB infants faces an environment very different to where it was developed. The skin is the first barrier that communicates with the dry, hard and pathogenic microorganisms-loaded external environment. It is the main organ that provides thermoregulation, immunity, and protection against dehydration and mechanical protection.

When a term NB is born, the first substance that covers the skin is vernix caseosa. This substance is made of antimicrobial peptides, sebaceous secretions, corneal cells and lanugo hairs which provide a high moisturizing power (it protects against insensible
water losses) as well as protection against the new coloniza-
tion of the skin of the NBs.5 Depending on the gestational age (GA) at birth, there will be more or less vernix caseosa.
For example, a post-term infant will have absorbed most of the vernix caseosa into the womb. That is why preterm and post-term NBs will not have that primary protection layer.6,7

The skin of a term NB is not considered mature until 3 weeks have passed; a preterm NB (PTNB) requires even longer time.8 All normal skin functions are altered in the PTNBs: protection against trauma or pressure, protection against ultraviolet rays, protection against infection, thermoregulation control and skin permeability. It is necessary to focus care on restoring the normal functions of the skin or alleviating its immaturity until the NB skin is completely developed.9

Neonatal PUs

The definition of PUs is given by research on adults. Currently, the international consensus continues to work on a definition for PUs, which evolves with new investigations and reviews. In 2014, the National Pressure Ulcer Advisory Panel (NPUAP), the European Pressure Ulcer Advisory Panel (EPUAP) and Pan Pacific Pressure Injury Alliance (PPPIA) recommended the following definition: “A pressure ulcer is localized injury to the skin and/or underlying tissue usually over a bony prominence, as a result of pressure, or pressure in combination with shear. A number of contributing or confounding factors are also associated with pressure ulcers; the significance of these factors is yet to be elucidated.”10

Other organizations have adopted similar definitions but with some modifications. Thanks to the new model created by García-Fernández et al,11 a PU is considered as a dependence-related injury. Thus, the National Group for the Study and Assessment of Pressure Ulcers (GNEAUPP)10,12 suggested in 2014 the following definition: “A pressure ulcer is a localized lesion on the skin and/or the underlying tissue, over a bony prominence, as a result of pressure, or pressure in combination with shear forces. Occasionally, they may also appear on soft tissues subjected to external pressure by different materials or clinical devices.”

PU etiology

The developmental mechanism of a PU is based on the poor blood supply to the tissue produced by a continuous pressure on an area.13–15 This pressure triggers occlusion of blood capillaries causing ischemia. Regarding the amount of pressure required for the capillary occlusion, and consequently for damaging the capillary, there is no consensus among different authors and investigations. Most studies show that pressure maintained over time and its intensity are directly proportional to the injury risk.12,15 In addition, it is known that other factors such as direction of pressure forces (friction and shear), as well as microclimate of the area, can increase the risk of tissue damage.12

PU classification

The international PU classification by the NPUAP/EPUAP/PPPIA describes four categories.10 As for category I, a non-blanching erythema is produced on intact skin; in category II, there is a partial loss of skin thickness or blisters may appear; in category III, there is a total loss of skin thickness; and in category IV, there is total loss of tissue thickness, with exposed muscle or bone. Besides these four categories, the NPUAP describes two additional categories: the fifth category is the “unclassifiable”, in which there is total loss of the skin or tissue thickness, and depth is unknown; The sixth category is the “suspected deep tissue injury”, with unknown depth.10

Neonatal risk factors and most frequent locations

Risk factors for pediatric and neonatal populations are similar to those for adults admitted to critical units. Although, due to the characteristics of neonatal patients, there are risk factors with greater strength related to the development of PUs. The main risk factors at neonatal age are the use of therapeutic and diagnostic devices (50–90% of the PUs in neonates),1,16 presence of endotracheal tube, use of noninvasive mechanical ventilation, hypotension and hypoxemia, prolonged stay in the neonatal intensive care unit (NICU), low birth weight (<2500 g) and prematurity (<37 weeks of GA).16–21

The most frequent locations of PUs in neonates are the occipital region and ears,22–24 as well as anatomical areas where therapeutic or diagnostic systems are at risk, such as fingers and feet (pulse oximetry sensor), skin support areas (vascular catheters), thorax (electrodes), ear lobe (capnaptic clamp sensor), nasal septum, back of the neck, nostrils and cheeks (continuous positive airway pressure interface, both binaural cannulae and face mask).20,23,25

Epidemiology

The scientific literature reveals a worldwide PU incidence ranging from 3.70 to 21.60% in the NICUs, with a prevalence of 23%.3,16,17,25–27 These data highlight the need to apply measures to prevent and treat PUs, especially in NBs, with clinical devices admitted to the NICU.
Due to the high incidence and prevalence of PUs in neonatal population as demonstrated in the literature and lack of studies dealing with prevention and treatment of PUs, our research team has performed a critical review of the literature to explain the preventive and treatment measures that may be used for PUs in the neonatal population.

Methods

We performed a narrative and critical review of the literature. We searched for articles related to PUs using a series of keywords. We selected those articles published up to 20 years ago, in Spanish or English language, and those that included the neonatal population.

Our study attempts to answer the following questions:

1. Which preventive measures for PUs have been investigated in the neonatal population in the last 20 years?
2. Which PU treatments can be used safely for neonates?

We searched the MEDLINE (through PubMed) with a research strategy shown in Table 1.

In parallel, as studies were included according to the criteria, manual searching was carried out on the bibliographic references from the registers included to detect relevant documents with the research question and that were not identified in the bibliographic search. For the manual search, it was taken into account that one of the authors of this article belongs to the Advisory Committee of the GNEAUPP and is Editor of the UPPPEDATRIA.org web, having at his disposal the main investigations carried out on PUs in neonates. Among the main documents taken into account, there were the Clinical Practice Guidelines of the EPUAP, NPUAP and PPIA, as well as the guidelines of the National Institute for Health and Care Excellence (NICE) or the clinical practice guidelines of the Sanitary Department of the Valencian Community (Spain).

Once all the documents were recovered, a selection process was carried out according to the eligibility criteria. Two members of the team reviewed independently the title and abstract for the inclusion of an article in the review. They used a register paper created for that end. If there was divergence, a third reviewer, blinded to the evaluations, settled if the article was accurate for the review. The final documents were distributed to the members of the research team, and the most relevant information on treatment and prevention of PUs in the neonatal population was extracted.

Results

Prevention

Preventive interventions in the neonatal population are based on four aspects: risk assessment, skin care, nutrition and pressure management.

Pressure Ulcer Risk Assessment Scales (PURAS): skin assessment and pressure ulcer risk rating scales

So far, only studies have been published on 14 scales used for the evaluation of PU risk in pediatric population. Of these, only four of these PURAS – Braden Q, Glamorgan Scale, Starkid and Neonatal Skin Risk Assessment Scale (NSRAS) – have been used in the neonatal population.32–35 The limited number of validated scales has to be added to the fact that the majority of scales used in the pediatric and neonatal population are adaptations of the adult scales and do not differentiate between a child or a neonate. Only one validated scale, Glamorgan Scale, was designed for pediatric population (neonates and children).32 This scale has been extensively studied and compared with other scales such

<table>
<thead>
<tr>
<th>Table 1 PubMed search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Search</td>
</tr>
<tr>
<td>#1</td>
</tr>
<tr>
<td>#2</td>
</tr>
<tr>
<td>#3</td>
</tr>
<tr>
<td>#5</td>
</tr>
</tbody>
</table>
Skin care depending on GA

Skin hygiene and hydration

During the first 2 weeks, skin hygiene is not recommended on a daily basis. Skin cleaning should only be done with warm water and cotton compresses or a soft material.44,45 The use of alkaline and antiseptic soaps should be avoided in preterm or low-birth-weight infants, and if used, they should be rinsed out properly.40,46,47 The use of soaps and creams of neutral pH, without preservatives, perfumes or coloring agents, should be evaluated for the safety of term infants (over 48 hours of life) or preterm infants (after 2 weeks, when the maturation of the PTNB skin occurs).46,48

It is advisable to hydrate the skin of NBs at risk for PUs (at term, after the first 48 hours) using emollients (oils, emulsion, milk) containing hyperoxygenated fatty acids, applied at individual dosages, to reduce both frequency and the severity of the PUs.34,44,45,49–51 In preterm infants, no ointment or topical cream or mineral oils should be used as a usual form of skin moisturizing due to the risk of contamination by coagulase-negative *Staphylococcus* or any bacteria, fungus or virus that causes nosocomial infection.52

In term NBs, vernix caseosa has higher water content and biomechanical defense properties than any cream, ointment or moisturizing solution. Therefore, it should not be removed until the first 48 hours of life or when the amount of vernix is low.5,53

Control and management of humidity

Excess moisture in the skin of the newborn should be avoided, as it favors the formation of PUs or moisture ulcers.3,44,54–57 It is necessary to take into account that infants are mixed incontinents, both of feces and of urine, and both substances can macerate the skin facilitating the appearance of PUs.33 Other factors that increase skin moisture, raising the risk of PUs, should also be considered. Some of these factors are the presence of ostomies or drainage, excess regurgitation or sialorrhea and the presence of noninvasive mechanical ventilation with heated and humidified systems (especially those systems that condense the water in the tubes).57–66

The main nursing care practices that can reduce humidity and therefore the PU risk are changing diapers, cleaning and drying the area after each episode of incontinence,67 applying absorbent dressings between the devices and the skin according to the needs of absorption (polyurethane, alginate, hydrocolloid fibers),62 and/or using barrier products tested in neonatal patients (creams, lotions, pastes and/or emollients enriched with zinc oxide, polyurethane spreads, molding pastes, silicones).60,44,55
Nutrition

Nutritional control is necessary because low birth weight, weight loss after 4–5 days of birth, malnutrition and dehydration may contribute to the development of PUs in NBs.3,31,45,68,69 It is recommended to evaluate the nutritional status in children with high risk of PUs or with presence of PUs using parameters such as weight, weight/height, cranial perimeter, body mass index and cutaneous folds in relation to GA.38,70

The energy expenditure of growth and the pathological process must be balanced by an adequate supply of nutrients. Therefore, it is necessary to measure fluids, proteins and calories based on anthropometric and clinical characteristics.71,72

Parenteral or enteral nutrition should be started as soon as possible for neonatal patients at risk of malnutrition for the prevention of PUs.39,73,74 However, breastfeeding should always be promoted through suckling, feeding bottle or enteral catheter.71

Pressure management

Local pressure relief devices

Local pressure relief devices are preferred for the prevention of secondary PUs to the use of therapeutic and diagnostic devices. Preventive interventions are shown in Tables 2 and 3.

At the occipital region, pressure relief devices such as gel or water, polyurethane and/or viscoelastic devices are also used.31,81–83 The use of hydrocolloid dressings is not recommended for redistribution of pressure, as they protect against friction but not against shear or direct pressure.24

Postural changes

The frequency of postural changes will be chosen depending on the PU risk evaluated using a validated risk scale, tolerance of the neonate to the manipulation, the presence or absence of PUs and the clinical stability of the neonate.24,39,71,84 Attempts should be made to combine all interventions (including postural changes) when NB is manipulated.31

NBs at risk for PU, that cannot be mobilized on their own and are not on a special surface for pressure management (SSPM), should be mobilized at least every 2 hours, as long as their clinical state allows it and accepts the manipulations that lead to change without being clinically altered.3,38,39,85,86 NBs over a high-performance support surface (static or dynamic) can be mobilized every 4 hours.87,88

Special surfaces for pressure management

Adult mattresses or SSPMs must not be used for neonates, as they are not suitable for their special morphology.38,84,89

The assignment of SSPMs should be protocolized to avoid their misuse (especially those with higher technology) and allow them to be assigned according to age, risk, body surface area, presence or absence of PUs, PU severity and baseline pathology of neonates.33,88,90,91

---

Table 2 PU preventive interventions for therapeutic clinical devices.

<table>
<thead>
<tr>
<th>Therapeutic devices</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIMV: interface use.</td>
<td>Remove the treatment when possibly.26</td>
</tr>
<tr>
<td>Endotracheal tube</td>
<td>Apply dressing or gel device that redistributes pressure.18,59,65,75</td>
</tr>
<tr>
<td>Drains and colostomies, ileostomy, nephrostomy</td>
<td>Leave a half-hour break between 4 to 6 hours of treatment.76</td>
</tr>
<tr>
<td>Venous catheters</td>
<td>Alternate nasal prongs with nasal mask.21,59,77</td>
</tr>
<tr>
<td>Nasogastric tube, urinary catheter</td>
<td>Do not attach with adhesive tape directly to the NB skin. Use adding devices in bridging form.45</td>
</tr>
<tr>
<td>Ostomy (gastro, trachea)</td>
<td>Change the pressure points of devices.62,78</td>
</tr>
<tr>
<td></td>
<td>Apply dressings between skin and device.3</td>
</tr>
<tr>
<td></td>
<td>Mobilize the catheter and nasogastric tube at list once a day.76</td>
</tr>
<tr>
<td></td>
<td>Mobilize the gastric device to avoid pressure at the same points.</td>
</tr>
<tr>
<td></td>
<td>Resizing the gastrostomy device when there is a clearance.62,78</td>
</tr>
<tr>
<td>Abbreviations: PU, pressure ulcer; NIMV, noninvasive mechanical ventilation; NB, newborn.</td>
<td></td>
</tr>
</tbody>
</table>

Table 3 PU preventive interventions for diagnostic clinical devices.

<table>
<thead>
<tr>
<th>Diagnostical devices</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulse oximetry sensor</td>
<td>Change the site sensor frequently (from 2 to 4 hours depending on risk).42,78</td>
</tr>
<tr>
<td>Capnography sensor</td>
<td>Do not hold the sensor with flexible tape.42,85</td>
</tr>
<tr>
<td>Electrocardiogram electrode</td>
<td>Do not force the tape over the sensor.42,80</td>
</tr>
<tr>
<td>Temperature sensors</td>
<td>Change location every 4 hours and monitor the sensor temperature.23,78</td>
</tr>
<tr>
<td></td>
<td>Place on the back when the patient is prone.76</td>
</tr>
<tr>
<td></td>
<td>Change position every 3 or 4 hours.78</td>
</tr>
<tr>
<td>Abbreviation: PU, pressure ulcer.</td>
<td></td>
</tr>
</tbody>
</table>
Static polyurethane foam surfaces (only a mattress or in combination with a head prevention device) have been shown to have a better cost-effectiveness ratio than dynamic SSPMs with low pressure constant. However, recent research has shown that certain reactive SSPMs (Figure 1) redistribute pressure better than static polyurethane surfaces. Despite the use of the latest generation of SSPMs, the occipital area must be highly protected compared to the other areas of the body. This zone is the one that maintains more pressure in children between the neonatal age and 2 years in all the mattresses studied.

The viscoelastic and gel surfaces are equally effective in preventing PUs. However, the viscoelastic ones have a better circumference and biparietal index and maintain the temperature better.

High-specification foam mattresses reduce pressure more than standard hospital mattresses and synthetic wool (lamb skin) surfaces.

Treatment
The PU treatment in neonates should be applied taking into account the following four crucial factors: systemic absorption rate of the active ingredient or its excipients, potential cytotoxicity, hypersensitivity to any component and possible adverse reactions. The resources available for neonates are less compared to the pediatric or adult population. The choice of the treatment must depend on the GA, PU category and its location, risk of infection, skin type and pathology.

Category I
It is necessary to differentiate between a category I PU and a blanching erythema (by means of digitopression or with a transparent disc). It is necessary to eliminate the source of pressure on the skin and to apply emollients (ointments, oils or emulsions) only in the affected area, using approved products. Essential fatty acids should be used with caution, as their effectiveness is not proven. When applying any product to the skin of a PTNB <32 weeks of GA, its effect should be monitored during the first 24 hours.

If it is not possible to remove pressure from the area, it will be necessary to apply a foam dressing with low adhesiveness (silicone or polyacrylate base) or without adhesive. The diameter of the dressing used in neonates must exceed that of the injured area by 1 cm.

Categories II, III and IV
Cleanings
A PU should be cleaned by irrigating the bed and the edges of the wound with physiological saline or sterile water using a 10–20 ml syringe and with a 20 G catheter (without needle). It is not advisable to use antiseptics for routine bed cleaning due to the risk of systemic absorption and potential cytotoxicity. Exceptionally, an antiseptic could be used only on the perilesional skin and if there is risk of bed contamination. After waiting for sufficient time to take effect, the antiseptic should be removed completely with physiological saline solution or with sterile water.

Debridement
Different debridement techniques can be performed to remove necrotic tissue. Autolytic debridement is the most commonly used in neonates due to its innocuousness (eg, use of hydrogel in gel or dressing). It is preferable to shear (partial or total), mechanical or enzymatic debridement. Sharp debridement in neonates should be chosen according to the PU location. A partial sharp debridement can be executed by a registered nurse, while a total shearing will be performed by a surgeon. Enzymatic debridement is not recommended, but if it is carried out, the product must be approved; for example, collagenase (not an approved product) will be replaced by another type of debridement.

For a category II PU, there are three intervention options: 1) keeping the blister and covering it with a dressing to avoid uncontrolled rupture; 2) puncturing the blister, draining the liquid and covering with a dressing to avoid a possible infection; 3) debriding the blister completely with scalp and tweezers, and covering with a dressing.

Exudate management
When there is excess of exudate in the PU, barrier products can be used on the perilesional skin. For those deep PUs with
a large amount of exudate, polyurethane foam dressings are recommended, together with hydrocolloid hydrofiber. For superficial and slightly exudative PUs, porous silicone meshes covered by sterile gauze or tubular mesh can be used.

**Bacterial colonization and infection management**

If there are signs of infection, it will be necessary to apply impregnated dressings with topical antiseptics (silver, polyhexamethylene biguanide) that are not contraindicated in neonates. When using silver, some authors recommend that an analytical control should be done within 2 weeks of being prescribed, followed by a resting period. The application of iodinated antiseptics is not recommended, which may favor the onset of hypothyroidism. Use of alcohols may cause irritation and necrosis. Topical antibiotics are associated with antimicrobial resistance and can cause adverse effects related to systemic absorption; specifically, neomycin may cause sensorineural deafness. Silver sulfadiazine should not be used in any format, as it can provoke argyria by systemic absorption, as well as kernicterus by the absorption of sulfadiazine.

**Healing stimulation**

Cure dressings in a humid environment (hydrogel, hydrocolloid, hydrocellular polyurethane foam and transparent semipermeable dressings) are found to show better results in the healing time compared to traditional or dry (gauze) dressings. The dressing choice depends on the healing phase. It is also recommended to use gauze previously moistened with saline or hydrogel. After the placement of the first cure dressing in a humid environment, the effect should be evaluated at 12–24 hours observing the wound bed. If gauze is used, it should be evaluated prior to its complete desiccation, that is, from 6 to 8 hours after placement, to avoid pain, erosion or trauma to the bed when it is removed. It is advisable to use silicone dressings and lipocolloid substances as they favor atraumatic removal. Calcium alginate dressings should be used with caution due to the systemic absorption of calcium and sodium. Combined dressings (hydrocolloid hydrofiber) and products with collagen should also be used with caution due to the risk of allergies and bleeding. There are fewer studies on the application of a barrier film between perilesional skin and adhesive dressing, although some authors do recommend it in infants older than 1 month.

**Negative-pressure wound therapy (NPWT)**

NPWT is indicated for neonates with stage III or IV PUs, after appropriate debridement, if there is no osteomyelitis. The foam dressing is placed directly onto the wound base, and a continuous negative pressure is set at −50 to −75 mmHg for younger children. When using NPWT for neonatal PUs, there is a risk of formation of PUs due to pressure from the tubing system. Care must be taken to prevent further pressure when placing tubing for NPWT, particularly over bony prominences.

**Conclusion**

PUs represent one of the most important iatrogenic lesions at hospital settings, which is why it is necessary to implement effective measures to resolve them. Despite the high incidence and prevalence of PUs in hospitalized neonates, no specific studies have been conducted in this population, and hence, the preventive and treatment recommendations are of low scientific evidence. Most of the recommendations are extrapolated from adult population studies and expert opinions. However, the anatomical and physiological characteristics of the neonates are different from the children and adults, and so the measures must be adapted to the neonatal population.

The treatment approach to PUs should be carried out in an interdisciplinary way, in which the nursing professionals should have a leading role, since PU prevention and application of treatment in the hospital setting is their responsibility.

PU prevention in neonates focuses on skin care (hygiene and hydration, moisture control and management), pressure management (local pressure relief devices, postural changes and SSPMs) as well as adequate nutrition. However, a fundamental part is the assessment of PU risk by valuation scales. The scales validated for PU risk detection in neonates are scarce, and are adapted from adult scales. This impairs the adequate assessment in neonates, and highlights the need to develop scales applicable in neonates of all GAs.

Only a few products are approved for PU treatment in neonates. The risk of systemic absorption, toxicity, hypersensitivity and possible adverse reactions that can occur in neonates due to the application of products designed for adults limit treatment options. Hence, it is necessary to use authorized products.

Further research is needed on both prevention and treatment of PUs, to determine which interventions and products should be used. Randomized clinical trials in different units of neonatal hospitalization may provide consistent results. Care should be standardized for the prevention and treatment of PUs that may reduce the incidence and severity of these in hospitalized neonates.

**Disclosure**

The authors report no conflicts of interest in this work.
References


